Avenda Health, based in Culver City, CA and led by CEO Shyam Natarajan, develops AI-enabled tools for prostate cancer care. Its core product, iQuest, is a deep-learning patient management software that maps a patient’s cancer in 3D and uncovers disease hidden within traditional MRI mapping. The FocalPoint System, powered by iQuest, provides an in-office ultrasound-guided soft tissue ablation option intended to preserve quality of life by sparing healthy tissue. FocalPoint is FDA cleared for soft tissue ablation, while iQuest and its use with FocalPoint are for investigational use only and not FDA cleared. The company says its software gives physicians precise, patient-specific information to support treatment decisions. Avenda plans to use new funding to accelerate adoption of iQuest and to continue clinical evidence development. Avenda Health is a biomedical device company based in Santa Monica that has developed a fiber-optic laser device to treat prostate tumors. The device is designed to ablate prostate tumors without compromising urinary or sexual function. The company was launched in June 2017 and was founded by Shyam Natarajan (CEO), Brittany Berry-Pusey (COO), and Dr. Leonard S. Marks (CMO). Avenda closed a funding round in which it sold $3,325,000 in securities to 18 investors, according to an SEC filing released April 11. The article does not report revenue, user metrics, prior financings, or commercialization status. Leadership includes Natarajan, an adjunct UCLA bioengineering professor who previously served as program manager of the UCLA Business of Science Center.

Total raised

$13M

Funding rounds

2

Latest round

Series B

Latest activity

Aug 2022